Nasdaq:US$13.41 (-0.23) | HKEX:HK$21.15 (+0.00) | AIM:£2.22 (+0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor